Search Results - Suzanne Doolen
- Showing 1 - 2 results of 2
-
1
Validation and in vivo characterization of research antibodies for Moesin, CD44, Midkine, and sFRP-1. [version 2; peer review: 2 approved, 1 approved with reservations] by Carl Laflamme, Allan I. Levey, S. J. Sukoff Rizzo, Riham Ayoubi, Sean-Paul G. Williams, Haian Fu, Ranjita Betarbet, Elizabeth Zoeller, Suzanne Doolen
Published in F1000Research (2024-04-01)Get full text
Article -
2
SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late‐onset Alzheimer's disease by Cynthia D. Jesudason, Emily R. Mason, Shaoyou Chu, Adrian L. Oblak, June Javens‐Wolfe, Mustapha Moussaif, Greg Durst, Philip Hipskind, Daniel E. Beck, Jiajun Dong, Ovini Amarasinghe, Zhong‐Yin Zhang, Adam K. Hamdani, Kratika Singhal, Andrew D. Mesecar, Sarah Souza, Marlene Jacobson, Jerry Di Salvo, Disha M. Soni, Murugesh Kandasamy, Andrea R. Masters, Sara K Quinney, Suzanne Doolen, Hasi Huhe, Stacey J. Sukoff Rizzo, Bruce T. Lamb, Alan D. Palkowitz, Timothy I. Richardson
Published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (2023-10-01)Get full text
Article
